Safety outcomes of disease-modifying therapies for relapsing–remitting multiple sclerosis: A network meta-analysis
Author:
Publisher
Elsevier BV
Subject
Neurology (clinical),Neurology,General Medicine
Reference32 articles.
1. Public availability of results of observational studies evaluating an intervention registered at ClinicalTrials.gov;Baudart;BMC Med.,2016
2. CDER, 2016. Program Description: Safety Outcomes Trials Subcommittee.[WWW Document]. URL https://www.fda.gov/media/101788/download.
3. Long-term safety evaluation of natalizumab for the treatment of multiple sclerosis;Clerico;Expert Opin. Drug Saf.,2017
4. Alemtuzumab CARE-MS II 5-year follow-up;Coles;Neurology,2017
5. Acute acalculous cholecystitis: a new safety risk for patients with MS treated with alemtuzumab;Croteau;Neurology,2018
Cited by 16 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Long‐Term Safety of Teriflunomide in Multiple Sclerosis Patients: Results of Prospective Comparative Studies in Three European Countries;Pharmacoepidemiology and Drug Safety;2024-07
2. Adverse Events Associated With Disease-Modifying Drugs for Multiple Sclerosis;Neurology;2024-02-13
3. Adverse effects of immunotherapies for multiple sclerosis: a network meta-analysis;Cochrane Database of Systematic Reviews;2023-11-30
4. A Real-World Experience of Azathioprine Versus First-Line Disease-Modifying Therapy in Relapsing-Remitting Multiple Sclerosis—A Prospective Cohort Study;Brain Sciences;2023-08-27
5. Safety and Monitoring of the Treatment with Disease-Modifying Therapies (DMTs) for Multiple Sclerosis (MS);Current Reviews in Clinical and Experimental Pharmacology;2023-03
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3